Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Fibrate / PPAR-α agonist

Ciprofibrate

Brand names: Modalim

Ciprofibrate is a fibrate lipid-regulating drug used in the management of dyslipidaemias, particularly where hypertriglyceridaemia is prominent.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

As a PPAR-alpha agonist it enhances lipoprotein lipase activity and fatty acid oxidation, lowering triglycerides and tending to raise HDL-cholesterol.

Prescribing in practice

  • Fibrates can cause myositis and rhabdomyolysis; risk is increased in renal impairment and when combined with a statin, so counsel on muscle symptoms and use combinations cautiously.
  • Avoid in significant hepatic or renal impairment and in gallbladder disease, as fibrates may increase the lithogenicity of bile.
  • May potentiate the effect of coumarin anticoagulants, requiring closer monitoring of anticoagulation.

Monitoring

Monitor the lipid profile for response, with liver function and renal function checks and creatine kinase if muscle symptoms occur.

Counselling the patient

  • Report unexplained muscle pain, tenderness or weakness promptly.
  • Continue dietary measures alongside the medicine.
  • Tell your clinician about any blood-thinning medicines you take.

Evidence & guidelines

Fibrates reduce triglycerides and are recommended by NICE chiefly for severe hypertriglyceridaemia rather than as first-line agents for cardiovascular risk reduction.

Reference: NICE CG181; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Pathways